← Browse by Condition
Medical Condition
solid tumors
Total Trials
12
Recruiting Now
12
Trial Phases
Phase 1, Phase 1, Phase 2, Phase 2
NCT05836324 Phase 1
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Enrollment
408 pts
Location
United States, Denma...
Sponsor
Incyte Corporation
NCT05536141 Phase 1
Recruiting
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Enrollment
362 pts
Location
United States, Austr...
Sponsor
Arcus Biosciences, Inc.
NCT06892379 Phase 1
Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
Enrollment
475 pts
Location
United States, China
Sponsor
Hansoh BioMedical R&D Company
NCT06809530 Phase 1, Phase 2
Recruiting
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Enrollment
34 pts
Location
China
Sponsor
Guangzhou Medical University
NCT07159126 Phase 1
Recruiting
A Study of DS3610a in Participants With Advanced Solid Tumor
Enrollment
70 pts
Location
Japan
Sponsor
Daiichi Sankyo
NCT04337177 Phase 1
Recruiting
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Enrollment
20 pts
Location
United States
Sponsor
Valent Technologies, LLC
NCT07032077 Phase 2
Recruiting
A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors
Enrollment
100 pts
Location
China
Sponsor
Shandong Suncadia Medicine Co....
NCT03744819
Recruiting
Biomarkers for Prediction of Tumor Response to Radiotherapy
Enrollment
100 pts
Location
China
Sponsor
Chuangzhen Chen
NCT07279428 Phase 1
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Enrollment
33 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT05238922 Phase 1
Recruiting
Study of INCB123667 in Subjects With Advanced Solid Tumors
Enrollment
604 pts
Location
United States, Franc...
Sponsor
Incyte Corporation
NCT06973863 Phase 1
Recruiting
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
Enrollment
40 pts
Location
Australia, Taiwan
Sponsor
PharmaEngine
NCT07158918 Phase 1, Phase 2
Recruiting
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Enrollment
65 pts
Location
United States, Austr...
Sponsor
ABL Bio, Inc.